## Dear Friends

Thank you for attending the two-day REACTA Forum 2023. The theme of this year's Forum was "Clinical Research in the New Era," and many speakers spoke on this topic. In Japan, the need for rapid vaccine development has become clear, and we have heard about the efforts of regulatory authorities, and we, Chiba University, have taken on the role of promoting vaccine development in cooperation with companies and regulatory authorities. In this regard, Dr. Yasuhiro Fujiwara, Chief Executive of the Pharmaceuticals and Medical Devices Agency, and Hiroshi Seino, Professor and Dean of the Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development, gave us lectures.

We also heard about the different experiences of academia, industry, and the regulatory agency in the Corona disaster and how we should respond in the post-Corona world where changes such as DCTs and RBAs have become necessary.

I am sure that each of us will return to our respective daily routines thinking about what challenges to take on next, how to work together and how to lead the world towards a more tolerant world. The next REACTA Forum will take place in Malaysia in May 2025. I hope to see you all at REACTA Forum 2025.

Finally, I would like to thank everyone who helped make this forum such a wonderful event, including the REACTA Board members, speakers, session chairs, and CCRC staff. This concludes the REACTA 2023 Forum. Thank you for your contributions.

Sincerely November 21, 2023

Chair of REACTA Forum 2023

Hídekí HANAOKA

Professor and chair of Chiba University Hospital Clinical Research Center (CCRC)